Team leaders : A Calmont (CR), C Chatziantoniou (DR), C Chadjichristos (CR), H Debiec (DR), JJ Boffa (PU-PH), JC Dussaule (PU-PH), H François (PU-PH), L Mesnard (PU-PH), P Ronco (PU-PH), D Buob (MCU-PH)
Team contributors : E Esteve (CCA), Y Luque (CCA), A Niasse (PhD), V Sahili (PhD), M Dao (PhD), C De Souza Almeida (Post-Doc)
Even though many aspects of the complex mechanisms orchestrating progression of renal disease have been identified, so far there is no specific treatment to slow down or prevent CKD progression. Therefore, identifying novel specific therapeutic targets and proposing more effective treatments against the progression of CKD is one of the major challenges of public health today. In the previous years, we were successful in identifying several new mediators of renal diseases having the potential to be targets for therapy. We will pursue this objective by investigating additional pathways of therapy: some, like Cx43, CB1 receptor and Sema3C, require inhibition because of their detrimental pro-inflammatory and pro-fibrotic action, whereas other, like Epac1 and podo γC, need activation because of their protective action. In addition, we are strengthening our approach by proposing innovative strategies that allow either a more efficient diagnosis or a targeted tissue-specific drug delivery.